Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-04-13

Clinical Trial Update: A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel [Phase 1]

View source ↗

Summary

Phase 1 study evaluating bioequivalence of Oraxol in cancer patients treated with intravenous paclitaxel has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oraxol
  • PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Athenex, Inc. | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2022-04-13